Other studies, such as those by (Mylona et al., 2008; Shipitsin et al., 2007; Kim et al., 2011; McFarlane et al., 2015), have suggested that CD44 expression is associated with a poor prognosis and can be considered a target for the treatment of breast cancer. This evidence concerns the gene CD44 and breast cancer.